Diabeloop’s closed loop insulin delivery system – a basic form of artificial pancreas – has become the second to be CE marked in Europe, two years after Medtronic’s Minimed 670G. The approval was based on the 68-patient WP7 trial, in which Diabeloop’s DBLG1 system allowed patients to spend more time in the target blood glucose range, and have fewer hypoglycaemic events, than patients who used an open-loop system consisting of a standard pump and sensor. The DBLG1 itself links a glucose sensor with a patch insulin pump via a smartphone-like device hosting Diabeloop’s algorithm, which can predict future blood glucose levels and deliver insulin accordingly. Having obtained CE mark, Diabeloop will now turn its efforts towards funding, and aims to close a round in the first quarter of next year. So far it has had just one infusion of funding, €13.5m ($15.3m) in the summer of 2017. Diabeloop has previously detailed its plans to get reimbursement for the system in Europe, develop a second-generation version and ultimately seek US approval (Diabeloop takes the collaborative route to Europe, May 11, 2017). It will need a sizeable venture haul if it is to achieve all that.